Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

Much has been made of the challenges Roche's blockbuster oncology troika faces with U.S. biosimilars hitting the market in quick succession. So far, those challengers haven't made much of a dent in Roche's sales stateside––but a new contestant could help tip the scales.